New research into acute myeloid leukemia could change future treatment approaches.

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Blackstone Life Sciences ("BXLS") today announced a research and development funding agreement to advance the clinical ...

(Beyond Pesticides. February 24, 2026) Leukemia is the leading contributor to the clear rise in childhood cancer cases over the last few decades, and the general association of pesticide exposures ...

Acute myeloid leukemia, or AML, is a rare and aggressive cancer that can affect people of all ages. Kiran Vanaja, an ...

Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

Total revenue of $68.7 million in 4Q25 and $172.4 million in FY2025 – – Revuforj® (revumenib) net revenue of $44.2 million in 4Q25, a 38% increase vs 3Q25, and $124.8 million in FY2025 – – Niktimvo™ ...

Fred Hutch Cancer Center hematologists took center stage at the 2026 Tandem Meetings, a multidisciplinary meeting of experts in the field of blood stem cell transplantation, held in Salt Lake City ...

The MACC Fund has committed $11.5 million to advance pediatric cancer research at the Versiti Blood Research Institute, ...

News, features, and commentary about cancer-related issues ...